| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Department of Human Genetics and Howard Hughes Medical Institute, University of Utah School of Medicine, Salt Lake City, Utah 84112-5331
Address all correspondence and requests for reprints to: Mario R. Capecchi, Department of Human Genetics and Howard Hughes Medical Institute, University of Utah School of Medicine, Salt Lake City, Utah 84112-5331. E-mail: mario.capecchi{at}genetics.utah.edu.
| ABSTRACT |
|---|
|
|
|---|
| INTRODUCTION |
|---|
|
|
|---|
Although the morphologic and histologic appearance of the murine uterus throughout development has been well established, the profile of genes that is critical to uterine proliferation and differentiation during the neonatal time period is unknown. Expression studies have revealed several factors present in the developing uterus including epidermal growth factor (EGF), EGF receptor (EGFR), keratinocyte growth factor (KGF), KGF receptor, and estrogen receptors (2, 3, 4, 5, 6). The importance of these genes in the proper development of the female reproductive tract, however, has not been established. Furthermore, estrogen receptors are prime examples of protein being present in uterine stroma throughout neonatal development (5, 6, 7), but not affecting uterine proliferation as evidenced by ovariectomy/adrenalectomy studies (8). This nonreliance of neonatal uterine growth upon estrogen is further evidenced by the normally developed reproductive tissues of both the
ERKO (estrogen receptor
null) and ßERKO (estrogen receptor ß null) mice (9).
Gene targeting studies have identified several genes with possible roles in uterine development. However, the exact role that some of these genes (Pax-2, Emx-2, Wnt-4) play in the growth and differentiation of the uterus cannot be ascertained due to the complete absence of the uterus in the mutant animals (10, 11, 12). Similarly, the exact role of Sp4, a transcription factor, in uterine differentiation and proliferation has not been established. Despite the findings of a reduced uterine size in the adult Sp4 knockout animal, neonatal uterine tissue was not examined (13).
In contrast, abnormal adult uterine morphology resulting from targeted gene disruptions has implicated the potential role of homeobox-containing genes in the development of the female reproductive tract. One of these homeobox genes, Hoxa11, is part of a family of genes that provides cells with specific positional identities, which result in the proper development and spatial arrangement of organs and structures along the anterior-posterior axis (14, 15). This genetic regulation consists of a set of structurally similar genes that were originally discovered in Drosophila through homeotic transformations (16). These genes possess a sequence of 180 bp (the homeobox) encoding a 60-amino acid DNA-binding motif (the homeodomain). In turn, the homeodomains are part of larger proteins that function as sequence-specific transcription factors (17). Currently, it is believed that the Hox genes, acting individually or in concert with each other, coordinate a multitude of downstream target genes that assemble functioning, region-specific tissue and organs (15, 18, 19, 20, 21).
Hoxa11 homozygous mutant adult females mice are sterile, producing no offspring when mated with their wild-type counterparts (22). The female Hoxa11 deficient mice produced a defective uterine environment with high embryo absorption rates in the homozygotes. Further investigations into the role of Hoxa11 gene in the differentiation and function of the female reproductive tract have revealed abnormal stromal and glandular cell development in adult mutant uteri (23). These same Hoxa11 adult female mutants also failed to display a normal decidual reaction secondary to natural or artificial stimuli (23). Taken together, Hoxa11 may be critical for normal uterine stromal cell and glandular differentiation and implantation.
Further evidence of the importance of Hoxa11 in the developing reproductive tract is suggested by the localization of Hoxa11 transcripts in the immature stromal cells of the Mullerian ducts of E14 embryos (22). Hoxa11 continues to be expressed in the stromal cells of the developing female reproductive tract and is also expressed in the uterine epithelial cells by 2 wk of age (24).
Despite the growing evidence of Hox gene involvement in the female reproductive tract, the exact role of Hoxa11 in uterine development is not known. More specifically, what cellular mechanisms and genes are altered in Hoxa11 mutants in the proper development of the murine uterus have not been established.
In this report, we investigate the role of Hoxa11 gene in the development of the female reproductive tract. At the histologic level, the Hoxa11 mutant uterus was observed to be identical to the wild-type uterus at the newborn stage and 7 d after birth. The amount of stromal tissue was moderately decreased in the Hoxa11 mutant uterus by d 14 after birth and was absent by d 21 after birth. Bromodeoxyuridine (BrdU) cellular proliferation studies demonstrated decreased cellular proliferation in the Hoxa11 mutant uterus both at 7 and 14 d after birth. Terminal deoxyribonucleotide transferase-mediated deoxyuridine triphosphate nick-end labeling (TUNEL) analysis demonstrated that apoptosis was markedly increased in the Hoxa11 mutant uterus at d 14 after birth. The expression of many genes involved in cell cycle regulation and apoptosis at both 7 and 14 d after birth was normal except for a marked decrease in p27. EGFR expression is dramatically decreased as evidenced by both real-time quantitative RT-PCR (QRT-PCR) and immunohistochemistry results. These findings suggest that Hoxa11 is involved in controlling cellular proliferation and apoptotic responses in the neonatal uterus and that the regulation of EGFR is critical to these processes.
| RESULTS |
|---|
|
|
|---|
|
|
|
|
Examination of the expression of several genes implicated in uterine development was also performed. Both EGF and EGFR have been implicated to play a role in the developing female reproductive tract by expression data (2) and EGFR-KO grafting data (28). Growth factors such as EGF and its receptor, EGFR, play critical roles in cellular proliferation and apoptosis (29). Alterations in the expression of either uterine EGF or EGFR in the Hoxa11 mutant could result in the abnormal stromal development found in the adults.
Gene targeting studies have identified several genes that may have roles in the developing reproductive tract. Wnt7a is a member of a family of genes patterning and cell-to-cell communication. Targeted removal of Wnt7a leads to abnormal female reproductive development and results in diminished stromal tissue and a reduced number of endometrial glands in the adult (30). Another Hox family member, Hoxa10, has also been implicated in proper reproductive tract development. In contrast to Hoxa11 mutants, Hoxa10 mutants only display abnormal uterine morphology in the proximal horn of the uterus (31).
The QRT-PCR data are reported as the fold change between wild-type and Hoxa11 mutants. Because we were looking for major differences in expression, which may have more biologic significance, we defined a change as greater than 2-fold difference. By QRT-PCR, there was no difference in mRNA levels of genes implicated in cell proliferation or apoptosis including cyclin A, cyclin B1, cyclin D1, cyclin E, BAX, or Bcl-2 transcripts between wild-type and mutant animals at 7 d after birth (Table 1
). In addition, the expression of genes implicated in uterine development, Wnt7a, Hoxa10, EGF, and EGFR, did not reveal any difference in transcript levels (Table 1
).
|
Genes implicated in the regulation of EGFR, Sp1 and p53, were also examined at 7 and 14 d of age. The transcription factor, Sp1, and the tumor suppressor, p53, have both been implicated in the regulation of EGFR (32, 33). The expression of Sp1 and p53 were found to be no different between wild-type and Hoxa11 mutants both at 7 and 14 d of age (Table 1
).
Altered Cell Cycle Mediator Gene in Hoxa11 Mutants
Based on the BrdU data, further examination was focused upon genes important in the cell cycle. By QRT-PCR, there was no difference in mRNA levels of genes implicated in the cell cycle including p15, p18, p21, p57, cdk2, cdk4, and cdk6 between wild-type and mutant animals at 14 d after birth (Table 2
). In contrast, pRB (retinoblastoma) transcript levels were slightly decreased by 2.07-fold and p27 transcript levels were markedly decreased by 7.1-fold in Hoxa11 mutant uteri. These data, taken together with decreased EGFR expression, suggest that Hoxa11 regulates genes essential for normal cellular proliferation in the developing female reproductive tract.
|
|
| DISCUSSION |
|---|
|
|
|---|
Interestingly, uteri from Hoxa11 mutants appear histologically normal in early neonatal stages and develop abnormalities as the animals increase in age. The findings of no discernible morphologic differences in uteri between Hoxa11 mutants and wild-type controls both at the newborn stage and d 7 after birth would suggest that Hoxa11 is not critical in establishing the Müllerian duct. Instead, our findings would indicate that Hoxa11 is necessary for the continued growth of the reproductive tract during the neonatal time period. The normal expression of Hoxa11 appears to be critical for stromal tissue development but not for epithelial or muscular development in the uterus. Despite the normal morphologic appearance of the epithelial and muscular components, however, the functionality of these tissues may be altered in the mutants. This is supported by the findings of a normal histologic appearance of three fourths of the uterus in Hoxa10 mutants but the inability to support implantation of wild-type embryos in this normal appearing area of the uterus (31).
The uterine hypoplasia seen in the Hoxa11 mutants is caused by a combination of increased stromal cell death with decreased stromal cell proliferation. Several investigators have previously found alterations in proliferation or cell death in other Hox mutants. Targeted null mutations in Hox genes in combination with transcription factors have been associated with both elevated apoptosis and decreased cell proliferation in the thymus of Hoxa3+/-Pax-/-mutants (34). In addition, elevated apoptosis with unaffected cellular proliferation has been detected in the hindbrains of Hoxa1 mutants and Hoxa1Hoxb1 double mutants (21, 35). Differential proliferation has also been proposed as a mechanism for Hox regulation of limb patterning and skeletal formation (25, 36). Thus, our data appear to implicate Hoxa11 in promoting proper proliferation and survival of stromal cells in the developing uterus.
We were unable to detect any major alterations (greater than 2-fold difference) in the expression of the majority of cell cycle regulators or apoptotic genes except for a marked decrease in p27, a small decrease in cyclin E and pRB. Cyclins, cyclin-dependent kinases (cdk), and cdk inhibitors are the major regulators of the cell cycle and are implicated in multiple cellular processes including cell proliferation and differentiation (26). Cdk inhibitor p27 is an antiproliferative mediator of the cell cycle and the p27 knockout animals have displayed organomegaly and cellular hyperplasia (37). Some investigators, however, have found p27 to be an activator of cdks (38), which is implicated by our findings of decreased p27 in the Hoxa11 mutants. Our results of altered expression of several cell cycle regulating genes may contribute to the abnormal cellular proliferation displayed in the Hoxa11 mutants.
Similar to cell proliferation and cell cycle regulation, apoptosis is a cellular process involving many pathways and numerous factors (39). Our choice of investigating only BAX and Bcl-2, two members of the Bcl-2 family, may again have limited our study. Expanding our investigation to include other apoptotic proteins may further enhance our understanding of how Hoxa11 regulates cell proliferation and apoptosis.
Hoxa11 does not appear to regulate Wnt7a in the developing uterus. Previous investigators have found that Wnt7a expression is necessary to maintain the expression of Hoxa11 in the uterus (30). Wnt7a mutants eventually lose the expression of Hoxa11 and Hoxa10 in the stroma of the adult uterus. Our finding of possible unaltered Wnt7a expression in the neonatal uteri of Hoxa11 mutants is consistent with the hypothesis that Hoxa11 is downstream of Wnt7a in the developing reproductive tract.
Although our findings show that Hoxa11 does not appear to regulate Hoxa10 in the developing uterus, the possibility still exists that other Hox genes may be altered in the developing uterus of Hoxa11 mutants. Other Hox genes besides Hoxa10 and Hoxa11 have been reported to be expressed in the uterus (24, 40, 41). In addition, the Hoxa13 null mutant displays agenesis of the caudal portion of the Müllerian ducts (42). Hox genes have also been demonstrated to regulate the expression of other Hox genes. Hoxa1 is required to establish the expression of Hoxb1 in the hindbrain (35) and the expression of Hoxb2 in rhombomere 4 of the hindbrain appears to be regulated by Hoxb1 (43). Therefore, determining whether other Hox genes may be altered in the uterus of the Hoxa11 mutant should provide further insights in the Hoxa11 regulation of the reproductive tract.
The uterine defects in Hoxa11 mutants may be, in part, mediated through EGFR. EGF and EGFR have both been implicated in uterine development, especially as mediators of estrogen action. The role of EGFR in the steroid-independent time period of neonatal uterine growth, however, is less well established. While the expression of both EGF and EGFR has been reported in the uterus of neonatal mice, no functional data exist (2, 3). Our findings of decreased EGFR transcript and protein in the stroma of Hoxa11 mutants point, for the first time, to the potential importance of EGFR in the proper development of the uterus in neonatal mice. Although the findings of unaltered expression of Sp1 and p53, both regulators of EGFR transcription, help point to the possibility of the direct regulation of EGFR by Hoxa11, the establishment of EGFR as a true transcriptional target of Hoxa11 would require further studies.
The examination of the uterus in EGFR knockout animals would further substantiate the importance of EGFR in the developing uterus. The EGFR knockout animal, however, survives up to only 8 d after birth (44). Our data seem to indicate that EGFR expression is normal in Hoxa11 mutants at d 7 after birth. Examination of EGFR knockout animals at older ages (d 14) would require a conditional knockout of EGFR.
In summary, we have demonstrated that the abnormal uterine morphology of Hoxa11 mutants arises during neonatal development and results from a combination of decreased cellular proliferation as well as increased cell death. The uterine expression of cell cycle regulators is altered in Hoxa11 mutants. We have also shown that EGFR expression is severely diminished in the stromal tissue of the neonatal mutants. Taken together, these findings suggest that Hoxa11 directly or indirectly regulates cellular proliferating genes and, in turn, controls cellular growth and apoptotic responses in the developing neonatal uterus.
| MATERIALS AND METHODS |
|---|
|
|
|---|
PCR assays, performed on genomic DNA, were used for genotyping to distinguish between wild-type and mutant alleles. Primers used to detect the Hoxa11 mutant allele were:
5'-GCTGGCTTTTATCTGAAGCCGG-3' (forward),
5'-CTCCCAATTCCAGTAGGCTGGA-3' (reverse),
5'-GGTTGTTCAGACTACAATCTGACC-3' (neo reverse).
Histologic Examination
Uterine tissues were obtained from wild-type and Hoxa11 mutant mice (C57BL/6 background) at newborn, 7, 14, and 21 d after birth. Tissues were fixed in 4% vol/vol paraformaldehyde and then embedded in paraffin. Tissue sections (5 µm) were deparaffinized and rehydrated for histologic, immunohistochemical and immunofluorescent analyses. For light microscopic examination, tissue sections were stained with hematoxylin and eosin.
BrdU Incorporation
For the assessment of cell proliferation, neonatal wild-type and Hoxa11 mutant mice were killed 2 h after BrdU (30 µg/g of body weight, Sigma Diagnostics, St. Louis, MO) was administered ip. Uterine sections obtained from BrdU-treated mice were fixed with 4% vol/vol paraformaldehyde and then embedded in paraffin. Tissue sections (5 µm) were deparaffinized, rehydrated and labeled with the 5-Bromo-2'-Deoxy-Uridine Labeling and Detection Kit II (Roche Molecular Biochemicals, Indianapolis, IN). The percentage of BrdU positive cells/1000 cells counted by three independent blinded evaluators was averaged. Statistical analysis was performed with the ANOVA statistical testing by using the SAS statistical package (SAS Institute, Cary, NC). Statistical significance was defined as P < 0.05.
TUNEL Labeling
Apoptosis was detected by using TUNEL analysis with the In Situ Death Detection Kit (Roche Molecular Biochemicals) on deparaffinized uterine sections. Samples were analyzed with confocal fluorescence microscopy.
Real-time RT-PCR
After genotyping, uteri were obtained from wild-type and Hoxa11 mutant mice at 7 and 14 d after birth. Six animals with identical genotypes in the 7-d-old groups (wild-type and Hoxa11 mutant), and four animals with identical genotypes in the 14-d-old group were pooled together to obtain sufficient total RNA for each sample. Total RNA was extracted with TRIzol (Invitrogen, Carlsbad, CA). One microgram of deoxyribonuclease I-treated RNA was reverse transcribed with Moloney murine leukemia virus reverse transcriptase (Invitrogen, Inc.) to generate cDNA.
Gene-specific primers corresponding to the investigated genes were used for the QRT-PCR. The primer pairs used are listed in Table 3
. QRT-PCR was performed with the LightCycler-based SYBR Green I detection system (Roche Molecular Biochemicals). Dilutions of cDNA were amplified at a specified annealing temperature determined by the specific primer pair. Amplification was followed by a melting curve analysis. Negative controls without cDNA were used to assess specificity. A stable housekeeping gene, glyceraldehyde-3-phosphate dehydrogenase (G3PDH) was used to control for input RNA. The amount of transcript was determined based on the fluorescence vs. cycle number plot. The cycle crossing point for each gene was determined by the LightCycler Software version 3.39 program (Roche Molecular Biochemicals). After adjusting with the G3PDH control, the difference in cycle crossing points were calculated for each gene between the wild-type group and mutants for a specific time point. For a theoretical efficiency of 100%, the fold difference was calculated by 2 to the power of the cycle point difference.
|
| ACKNOWLEDGMENTS |
|---|
| FOOTNOTES |
|---|
Abbreviations: BrdU, Bromodeoxyuridine; cdk, cyclin-dependent kinase; EGF, epidermal growth factor; EGFR, EGF receptor; G3PDH, glyceraldehyde-3-phosphate dehydrogenase; KGF, keratinocyte growth factor; QRT-PCR, quantitative RT-PCR; TUNEL, terminal deoxyribonucleotide transferase-mediated deoxyuridine triphosphate nick-end labeling.
Received for publication June 9, 2003. Accepted for publication October 3, 2003.
| REFERENCES |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
V. J. Lynch, A. Tanzer, Y. Wang, F. C. Leung, B. Gellersen, D. Emera, and G. P. Wagner Adaptive changes in the transcription factor HoxA-11 are essential for the evolution of pregnancy in mammals PNAS, September 30, 2008; 105(39): 14928 - 14933. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. C. M. Simmen, R. R. Eason, J. R. McQuown, A. L. Linz, T.-J. Kang, L. Chatman Jr., S. R. Till, Y. Fujii-Kuriyama, F. A. Simmen, and S. P. Oh Subfertility, Uterine Hypoplasia, and Partial Progesterone Resistance in Mice Lacking the Kruppel-like Factor 9/Basic Transcription Element-binding Protein-1 (Bteb1) Gene J. Biol. Chem., July 9, 2004; 279(28): 29286 - 29294. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Daikoku, H. Song, Y. Guo, A. Riesewijk, S. Mosselman, S. K. Das, and S. K. Dey Uterine Msx-1 and Wnt4 Signaling Becomes Aberrant in Mice with the Loss of Leukemia Inhibitory Factor or Hoxa-10: Evidence for a Novel Cytokine-Homeobox-Wnt Signaling in Implantation Mol. Endocrinol., May 1, 2004; 18(5): 1238 - 1250. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |